COAG.US Hemab Therapeutics Holdings, Inc. Common Stock

Healthcare Biotechnology USA Stocks
40.86 USD
Close of Nov 14, 2026
18.00 55.42
Market cap
USD 1.91B
P/E
-
P/B
4.28x
ROE
-23.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is COAG.US undervalued?

Graham number

The Graham number of Hemab Therapeutics Holdings, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hemab Therapeutics Holdings, Inc. Common Stock fundamental analysis

No fundamental analysis for Hemab Therapeutics Holdings, Inc. Common Stock yet.

Hemab Therapeutics Holdings, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor …

Full company profile